Alphavirus-based vaccines

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 1, 2002, Pages 28-34

  Lundstrom, Kenneth ^a  

^a Regulon Inc   (Switzerland)

Author keywords

Alphavirus; Replication deficient virus; Replicon; Vaccine

Indexed keywords

MONOCLONAL ANTIBODY; NUCLEIC ACID; PLASMID DNA; RNA; TUMOR VACCINE; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA VECTOR; DRUG MANUFACTURE; GENE AMPLIFICATION; GENE EXPRESSION; HOST CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PROPHYLAXIS; REPLICON; SEMLIKI FOREST ALPHAVIRUS; TRANSGENE; VIRUS GENE; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION; WART VIRUS;

ALPHAVIRUS; ANIMALS; CANCER VACCINES; GENETIC VECTORS; HUMANS; NEOPLASMS; RECOMBINATION, GENETIC; VACCINES, DNA; VACCINES, SYNTHETIC;

ALPHAVIRUS; ANIMALIA; HUMAN PAPILLOMAVIRUS TYPES; SEMLIKI FOREST VIRUS;

EID: 0036086402     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon
2. Sindbis virus: An efficient broad host range vector for gene expression in animal cells
3. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant
4. Alphaviruses as tools in neurobiology and gene therapy
5. Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures
6. Efficient in vivo expression of a reporter gene in rat brain after injection of replication-deficient Semliki Forest virus
7. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography
8. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles
9. DNA and RNA-based vaccines: Principles, progress and prospects
10. Alphavirus vectors: Applications for DNA vaccine production and gene expression
11. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218
12. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine
13. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate
14. The alphaviruses: Gene expression, replication and evolution
15. Specific Sindbis virus-coded function for minus-strand RNA synthesis
16. Sindbis virus nsP1 functions in negative-strand RNA synthesis
17. Cleavage-site preferences of Sindbis virus polyproteins containing the non-structural proteinase. Evidence for temporal regulation of polyprotein processing in vivo
18. Functional defects of RNA-negative temperature-sensitive mutants of Sindbis and Semliki Forest viruses
19. Solubilization and immunoprecipitation of alphavirus replicon complexes
20. Mapping of RNA-temperature-sensitive mutants of Sindbis virus: Assignment of complementation groups A, B, and G to non-structural proteins
21. Self-replicating Semliki Forest virus RNA as a recombinant vaccine
22. A plasmid-based self-amplifying Sindbis virus vector
23. Enhancing immune response using suicidal vaccines
24. Semliki Forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells
25. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles
26. Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein
27. Naked RNA immunization with replicons from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T-cell response against the influenza A virus nucleoprotein
28. Mucosal immune responses associated with polynucelotide vaccination
29. Comparative analysis of humoral immune responses to HIV type I envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus partcles
30. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type I immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector
31. Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: A comparative study using multivalent vaccine approaches
32. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus
33. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins
34. A recombinant Semliki Forest virus particle vaccine encoding the prME and NS1 proteins of louping ill virus is effective in a sheep challenge model
35. Layered amplification of gene expression with a DNA gene delivery system
36. Alphavirus vectors for gene expression and vaccines
37. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunization encoding a secreted RSV G protein-derived antigen
38. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus
39. DNA immunization against herpes simplex virus: Enhanced efficacy using a Sindbis-based vector
40. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters
41. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine
42. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki Forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens
43. Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development
44. Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332
45. Semliki Forest virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems
46. Marburg virus vaccines: Comparing classical and new approaches
47. Maintenance of CD(+) T-cell memory following infection with recombinant sindbis and vaccinia viruses
48. Cancer therapy using self-replicating RNA vaccine
49. Induction of P185 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene
50. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 e7 RNA
51. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus-mediated complementary DNA
52. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
53. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments
54. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein
55. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen
56. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene
57. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen
58. Gene gun mediated vaccination is superior to manual delivery for immunization with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus
59. Individual and bivalent vaccines based on alphavirus replicon protect guinea pigs against infection with Lassa and Ebola viruses
60. Noncytopathogenic Sindbis RNA vectors for heterologous gene expression
61. Replicon vectors derived from Sindbis virus and Semliki Forest virus that establish persistent replication in host cells
62. Novel mutant Semliki Forest virus vectors: Gene expression and localization studies in neuronal cells
63. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: Plasmid dependence of muscle damage and effect of poloxamer 188
64. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge
65. Generation of monoclonal antibodies to naive human immunodeficiency virus type I envelope glycoprotein by immunization of mice with naked RNA
66. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chicken against lethal infection with Hong Kong-origin H5N1 viruses
67. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV injection
68. Replicon-helper systems from Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
69. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge
70. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice
71. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and non-human primates
72. DNA-based and alphavirus-vectored immunization with prM and E proteins elicit long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus
73. Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy
74. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
75. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine
76. Enhance simian immunodeficiency virus-specific immune response in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara
77. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles